At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed DLBCL per WHO classification
- ✓Evaluable lesions on PET/CT
- ✓Life expectancy >3 months
- ✓Relapsed/refractory disease: no remission within 90 days of first-line therapy or progression after first-line therapy, with ≥2 weeks washout
- ✕Pregnant or lactating women
- ✕Hepatitis B (HBV-DNA >detectable limit) or Hepatitis C (HCV) infection
- ✕HIV infection or other acquired/congenital immune deficiency disorders
- ✕History of DVT or PE within past 12 months
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05348213Phase 2RecruitingUpdate OverdueUpdated 20mo ago · Completion was 13mo agoClinical Study of Efficacy and Safety of Novel Targeted Drugs Combined With R-ICE Regimen in the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Zanubrutinib plus R-ICE, Decitabine plus R-ICE, and 3 other interventions for Diffuse Large B Cell Lymphoma. Currently recruiting, targeting 76 participants across 1 site.
Signals
Detailed Summary
A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.
Study Details
Timeline
Interventions
Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3